Liraglutide likely helps more adults with obesity reach a weight-loss threshold
Weight-loss threshold results were more certain than some broader health outcomes; adverse events may increase.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
For adults with obesity, liraglutide likely increases the chance of reaching a weight-loss threshold compared with placebo, with evidence suggesting this persists at longer follow-up. Broader health effects were less clear: several outcomes remained uncertain or showed little meaningful difference, and adverse events, including serious ones, may increase.
This abstract-based summary reflects mostly manufacturer-funded trials. Few studies supplied longer follow-up, and evidence certainty varied substantially across outcomes.
What researchers found
Reaching at least 5% weight loss
Liraglutide versus placebo at 26 to 68 weeks; moderate-certainty evidence. The 95% confidence interval gives an uncertainty range of 1.80 to 2.45 times as likely.
Different weight outcomes
Researchers separated the proportion reaching a weight-loss threshold from the average percentage change in weight. Evidence for the average change was very uncertain at medium-term follow-up, even though evidence for reaching the threshold was more reliable.
Broader health outcomes
The review judged medium-term results as showing little clinically meaningful difference in major adverse cardiovascular events and little difference in physical-function quality of life. Effects on mortality were very uncertain, so weight results alone cannot establish these benefits.
The original publication
Liraglutide for adults living with obesity.
Meza N, Bracchiglione J, Escobar Liquitay CM et al.
Cochrane Database Syst Rev · 2025
- PubMed ID
- 41161684
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.